Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.


Player Avatar OklaBoston (69.29) Submitted: 4/8/2013 11:31:51 AM : Outperform Start Price: $4.67 GALT Score: -13.18

The CEO and multiple directors bought on the open market recently, and the current ratio is a whopping 7.73. I'd call that good fundamental justification for the chart uptrend that started a few months ago, wouldn't you?

Featured Broker Partners